COMPANY PROFILE

ProVerum

Explore full profile

Redefining Minimally Invasive Treatment for BPH

Dublin, IrelandFounded 2016Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About ProVerum

Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin, developing novel treatment solutions for patients with symptomatic benign prostatic hyperplasia (BPH).

Read full description

ProVerum has developed a minimally invasive implant for patients with symptomatic Benign Prostatic Hyperplasia (BPH) as an alternative to invasive surgery.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Dublin, Ireland
Employees: 54
Open positions: None listed
Dealroom signal: 95.0/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, medical implants, Surgery, Catheters, Spinout, EIC, Sextech
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Aug 2025	$80M	$320M	Enterprise Ireland · OrbiMed · Ireland Strategic Investment Fund · Atlantic Bridge University Fund	↗
EARLY VCOther financing	Nov 2023	$17M	$165M	Lightstone Ventures · Irrus Investments · Medtech	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	Margin
2026
2025
2024
2023
2022		—
2021	—	—	—
2020	—	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

ProVerum website traffic

Latest recorded traffic for ProVerum is 1.4K monthly website visits, up 91.8% over the last three months. ProVerum's team grew 45.9% over the past year.

Latest monthly visits1.4K 3-month web change+91.8% 1-year team growth+45.9%

Monthly website visitsJun 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Professional & Commercial Training Manager – Programs & Field AssessmentsMinneapolis, MN · Other · Aug 27, 2026 Professional & Commercial Training Manager – Training DeliveryMinneapolis, MN · Human Resources · Aug 27, 2026 Product EngineerDublin, County Dublin, Ireland · Business Development · Aug 26, 2026 Senior Product EngineerGalway, County Galway, Ireland · Business Development · Aug 13, 2026 Product EngineerGalway, County Galway, Ireland · Business Development · Aug 12, 2026 Supply Chain ManagerGalway, County Galway, Ireland · Logistics · Aug 12, 2026 Product Engineer (R&D)Galway, County Galway, Ireland · Business Development · Jul 30, 2026

7 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
INInossiaProviding solutions that have been adapted to the mechanical properties of brittle osteoporotic bone	Stockholms kommun, Sweden	Operational	11	$3.7M	$9.9M
SBSUN bioscienceEnabling personalized medicine through patient-specific organoids cultured on high-throughput 3D microwell platform	Lausanne, Switzerland	Operational
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
CRCroivalveTreating Heart Valve Disease	Dublin, Ireland	Operational
AMAVeta MedicalMedical device company delivering the only non-hormonal, affordable, safe targeted therapy for Vaginal Atrophy sufferers	Galway, Ireland	Operational
OPOptellumDeveloping an artificial intelligence software platform to support clinicians in lung cancer nodule management	Oxford, United Kingdom	Operational
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational
DIDiabeloopMedical device company for diabetes and closed-loop system and also develops disruptive technological innovations to automate the treatment of diabetes	Grenoble, France	Operational